Announcement PDF INVESTOR PRESENTATION | MARCH 2026 BPH GLOBAL LIMITED (ASX: BP8) www.bphglobal.com BPH Global – The New Force in Seaweed Bio-Technology Offer Information and Disclaimer This investor presentation (the “presentation”) is for informational purposes only and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any equity, debt or other financial instruments of BPH Global Limited (BP8). The presentation has been prepared to assist parties in making their own evaluation and for no other purpose. Parties should further carry out their own due diligence. It is not intended to form the basis of any investment decision or any other decisions. No Representation or Warranty No representation or warranty, express or implied, is or will be given by BP8 or any of its respective affiliates, directors, officers, employees or advisers or any other person as to the accuracy or completeness of the information in this presentation or any other written, oral or other communications transmitted or otherwise made available to any party in the course of its evaluation, and no responsibility or liability whatsoever is accepted for the accuracy or sufficiency thereof or for any errors, omissions or misstatements, negligent or otherwise, relating thereto. This presentation does not purport to contain all of the information that may be required to evaluate a possible investment opportunity with respect to BP8, and does not constitute investment, tax or legal advice. The recipient also acknowledges and agrees that the information contained in this presentation is preliminary in nature and is subject to change, and any such changes may be material. BP8 disclaims any duty to update the information contained in this presentation. This presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this presentation may be listed without the TM, SM© or ® symbols, but parties assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade names and copyrights. No Offer or Solicitation This presentation shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities. This presentation shall also not constitute an offer to sell or the solicitation of an offer to buy any securities. No offer, sale or solicitation of any securities shall be made in any jurisdiction in which such offer, sale or solicitation would be prohibited. BP8 does not provide investors with personal advice that any investment made will be suitable for the investor’s personal circumstances or investment objectives. No representation or warranty is given by BP8 that any investment with respect to BP8 is suitable for the investor or that it will meet the investor’s investment objectives. Eligible Recipients This presentation is provided to you as an investor to whom an offer document is not required to be given, and no registration, lodgement or other formality is required, in connection with an offer of securities. In accepting this presentation, you warrant that you are an investor within the scope of this paragraph and that you accept this presentation on the basis set out in this notice. This presentation is not, and does not constitute, or form any part of, an offer to sell or the solicitation, invitation or recommendation to purchase any securities in the United States and neither this presentation nor anything contained herein shall form the basis of any contract or commitment. The distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. Forward Looking Statements This presentation contains “forward-looking statements”. These statements are based on management’s current expectations and beliefs, as well as on a number of assumptions concerning future events. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which are outside of our control and all of which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements. BP8 may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements and the forward- looking statements should not be unduly relied upon. We do not undertake any obligation to update forward-looking statements following the date this presentation is made. Any industry, market or other, similar data have been compiled from sources thought to be reliable, but have not been verified, and no assurance can be made as to their accuracy. Risks Please refer to Appendix 1 for Key Risks 2 3 Company Overview ASX Ticker BP8 Share Price (6 March 2026) A$0.002 Shares on Issue 2.35bn Market Cap $4.7m Cash $0.9m Enterprice Value $3.8m Top 20 Shareholding 49.5% Major Shareholders Holding % Matthew Leonard 121,166,668 5.15% Atidim Investments Pty Ltd 107,162,506 4.55% Apertus Capital Pty Ltd 105,498,941 4.48% Peter Andrew Proska 100,066,667 4.25% Adman Lanes Pty Ltd 85,000,000 3.61% Company Snapshot Transforming Seaweed into Solutions for a Sustainable Future Board of Directors & Key Management Matthew is an accomplished and internationally proven business development professional. With over 12 years of outstanding record of achievement in demanding, complex and highly competitive markets. He possesses expertise across advertising, marketing and media event management sector, with recent focus on linking opportunities with high-net-worth individuals throughout Asia. Matthew Leonard - Managing Director/CEO Francesco is an experienced public company director with significant business and investment experience working with companies operating across various industry sectors. Mr Cannavo has been instrumental in assisting many listed and unlisted companies achieve their growth potential by providing strategic advice on raising investment capital and completing strategic acquisitions. Francesco Cannavo – Executive Director Paul was a partner of HWL Ebsworth Lawyers for thirteen years before retiring from the partnership in 2017. Mr Stephenson remains a consultant with HWLE. Mr Stephenson specialises in public and private equity fundraising, initial public offerings, backdoor listings and reverse mergers (both in Australia and the United States), and mergers and acquisitions involving both private and listed companies Paul Stephenson – Non-Executive Chairman With over 20 years of experience across Indonesia's trading, mining, manufacturing, and investment sectors, he specialises in driving growth in challenging and emerging markets. As a board member and shareholder at Mitra Agro Global, along with other ventures, he has successfully led large-scale projects with a focus on sustainable and profitable growth. His leadership approach emphasises building resilient teams and forming strategic partnerships to maximise long-term value Deepak Jha – Director of Operations Investment Highlights Significant market opportunity, with the global seaweed market size of approximately $28bn Seaweed trading continues to strengthen, with revenues in the first 8 months of trading totalling $2.15m, growing at an annualised CAGR of 310% R&D Pipeline of high margin seaweed products, with clear path to near term commercialisation Global partnerships including a commercial agreement with the Indonesian provincial government for seaweed supply and bio- stimulant manufacturing BPH Global is pioneering the integration of biotechnology, marine science, and sustainable development to deliver high-value products derived from seaweed, one of the planet’s most versatile and renewable natural resources. BPH’s approach spans the full value chain from sustainable farming and strategic sourcing to advanced processing and global marketing, ensuring traceability, quality and environmental responsibility at every stage. A High-Growth $28bn Global Seaweed Opportunity Source: Umashree andK. Arunkumar (2023), Zannie Langford (2024),Alginate Market Size, Trends Growth Forecast Report 2032, Agar Market Size, Trends,Outlook & Forecast by 2033| FMI. $23.0bn Food & Ingredients $2.0bn Hydrocolloids $3.0bn Biostimulants/ Plastics Total Addressable Market1 $28bn Total Addressable Market 12.3% Annual Growth Rate #1 Indonesia world largest seaweed producer 3 Target Markets Asia, Europe, North America BPH Global Strategic Overview Seaweed Trading Performance ❖ Aggregate gross sales of $2.36 million AUD within the first 9 months of trading operations ❖ Revenue growth of 156.5% since the first month of trading. ❖ BPH remain focused on continuing the momentum into 2026 by expanding independent trading volumes through Makassar, strengthening supply chain resilience and sourcing networks, deepening domestic and international customer relationships; and progressing export readiness under the Company’s Seaweed Export Licence BPH continues to advance its strategy of increasing the proportion of sales conducted independently through its Makassar-based warehouse and operating platform 0 100000 200000 300000 400000 500000 600000 Revenue (AUD) M1 May-Jun 25 M2 Jun-Jul 25 M3 Jul-Aug 25 M4 Aug-Sep 25 R&D & Commercialisation Project Timeline 9 R&D & Commercialisation Program Highlights PRINCIPAL R&D GOALS R&D activity that is focused on value-added products that attract higher sales margins Extraction of seaweed-based nutraceuticals and pharmaceutical ingredients to infuse into food, nutrition, healthcare, health supplements, cosmetics and personal care products, Bio stimulants and Biomass Deployment of separate processing pathways to produce biofuels or extract critical minerals from seaweed biomass for sale into the energy, EV battery and minerals industry. SEAWEED BASED BIO FUEL  R&D program is focused on developing renewable biofuel opportunities from seaweed biomass generated through its existing operations.  Seaweed biomass when broken down by fermentation in the Company’s existing operations produces biohydrogen and other biogases as a by-product.  As the Company’s fermentation-based activities approach commercialisation, proposed to similarly upscale production of biogases in accordance with the outcomes of its R & D program.  Seaweed biomass can also be processed using hydrothermal liquefaction (HTL) to produce biocrude, a renewable liquid biofuel.  The Company’s R&D program will focus on optimizing biogas production from fermentation and biocrude production from HTL processing of seaweed biomass.  Potential ESG advantages of seaweed-derived biofuels compared with many land-based biofuel feedstocks, include no requirement for arable land, freshwater or fertiliser inputs. Seaweed Based Product Brand Development Health Beverage, Nutraceuticals & Supplements 11 Probiotic/postbiotic Health Seaweed based kaffir drink Formulation completed / Singapore Polytechnic collaboration Productive discussions with NZ based water manufacturer / global sales/marketing distribution Male Vitality Products Natural Formulations for Male Vitality & Performance Enhancement Integrated TCM & Marine Performance Formulation • TCM-inspired botanical foundation combined with marine bioactive components • Structured to support vascular function, stamina, and overall male vitality • Clean-label, non-pharma positioning • Designed for pre-activity or structured supplementation use • Regulatory strategy includes pursuing TGA compliance in Australia prior to China market entry • Currently exploring engagement with China-based e- commerce platforms for: - Direct-to-consumer distribution - Broader international market access Proposed Seaweed based Biostimulant Platform Developed Jointly by BPH Global × Temasek Polytechnic | Indonesia Production → Farmer Impact Seaweed Farms Sustainable seaweed cultivated in Indonesian coastal regions Extraction Plant in Indonesia Seaweed processed into concentrated biostimulant extracts Distribution Network Cooperatives and government agricultural programs Farm Application Farmers apply product to improve crop growth and resilience Harvest Payment Farmers pay after harvest when crops are sold Strategic Impact ❖ Higher crop yields and farmer income ❖ Reduced chemical fertilizer dependence ❖ Large-scale adoption through cooperative distribution ❖ Monetisation of Indonesia’s seaweed resources Animal Feed and Feed Supplement Converting non-export grade seaweed into Animal Feed/Supplementation R&D program launched to assess animal feed / feed supplement applications for non-export grade Raw Seaweed Biomas Low-risk, low-cost approach leveraging existing Indonesia-based operations and sourced material (no immediate change to core trading/export business) Value uplift from existing supply chain: monetise “out-of-spec” seaweed by improving utilisation, reducing waste, and supporting margin resilience Key workstreams: nutritional & functional properties, animal health outcomes, and potential methane-reduction characteristics in feed formulations 14 Seaweed Bioremediation Mass Scale Natural Solution Using Algal Biomass Bio remediation of ocean areas adjacent to mineral smelters using BP8 seaweed technology Discussions with Indonesian government & Indonesian based mining companies ( min 12 month contacts) Seaweed a hyperaccumulator of REE’s & Critical Minerals Ongoing R&D with Temasek Polytechnic & Marchwood Labs on identification & extraction 15 BPH Global (ASX: BP8) — Near-Term Catalysts Seaweed Trading Growth ~A$2.4M annual revenue run-rate Indonesia sourcing network Scale to >1000 MT/month potential Target 2026-2027 Seaweed Biostimulant Agri-yield enhancement product Indonesia farmer distribution model Field trials and pilot programs Project Popeye – Men's Supplement Seaweed-derived nutraceutical R&D with Temasek Polytechnic Commercialization target: Q42026 Seaweed based Probiotic Drink Launch in Partnership with Beverage Company Potential markets in China, SG & ANZ Test Market in next 3 months. Control Main Ingredients Processing Transitioning from Seaweed Trading to High Value Marine Biotechnology with strategic Partners Fucoidan Extraction for Anti-Ageing Seaweed-derived nutraceutical MOU for commercialization with BRIN ( Indonesia) Commercialisation target: Q4 2026 Growing Market Appreciation of Seaweed’s Commercial Potential 17 Seaweed-based Cattle Feed to reduce methane emissions Sea Forest Market Cap $140 Million – Cattle feed BPH GLOBAL LIMITED (ASX:BP8) www.bphglobal.com • Chairman: Paul Stephenson • Email: paul.stephenson1@icloud.com • CEO: Matthew Leonard • Email: matthew@goldenventurecapital.com Reinvigorated management driving a commercially sensible business plan Deep expertise in sourcing and cultivating seaweed and the extraction of minerals, nano minerals and nutraceuticals from seaweed Business focus on sales into new and existing markets and new business opportunities New Business Opportunities sought and welcomed to grow the Company’s operations and revenue 18 There are specificrisks which relate directly to the Company’s activities. In addition, there are other general risks, many of which are largelybeyond the control of the Company and the Directors. The risks identified in this section, or other risk factors, may have a material impact on the financial performance of the Company and the market price of the Company’s securities. The following is a summaryof the more material matters to be considered and should be readin conjunction with specific matters referred to in the Company’s announcements and reports. However, the summary is not exhaustive and potential investors shouldconsult their professional advisors before deciding whether to applyfor securities in the Company. Appendix 1: Key Risks Business development and commercialisation The Company is focused on producing foods andproducts which deliver Traditional Chinese Medicine (TCM)-based health outcomes and the development of technologies to enable the extraction of hydrogen and minerals fromseaweed for use in the energyandbatteryindustries. Regarding TCM products, the Companyfocuses on the research & development (R&D), production and commercialisation of bird’s nest and plant-based products, including seaweed and sea plants and hemp, to produce sustainable bird’s nest andplant-based protein foods and nutraceutical and pharmaceutical ingredients (includingCBDextracted from Hemp) for utilisation in the food, nutrition, healthcare, health supplements, cosmetics andpersonalcare industries. Regardingthe energy and batteryindustries, the Companyfocuses its R&D on the extraction of hydrogen and minerals fromseaweed, leveraging its technologies developed for the extraction of nutraceuticals from seaweed. There can be no guarantee that the resulting products or extracted hydrogen and minerals will be commercialised, will be competitive in their respective markets, or will perform satisfactorily to their intended application. Funding Any inability of the Company to obtain additional funding as required, including under the proposed capitalraising, would have a material adverse effect on the Company’s business, its financial condition and performance and its ability to continue as a going concern. Accordingly, there is a material uncertainty that may cast doubt on the Company’s ability to continue as a going concern. Shouldthe Company not be able to continue as a going concern, it may be required to realise its assets and discharge its liabilities other than in the ordinary course of business, and at amounts that differ from those stated in the Company’s financial statements. Research and development risk In order to remain competitive, the Company intends to continue to undertake research and development. The Company makes no representation that any of its research into or development of its technologies and products will be successful or that its technologies will be developed into products that are commerciallyexploitable. Armed conflicts The market price of the Company’s Shares and Options may be adversely affected in the short to medium termby the economicuncertaintycaused by the Ukraine conflict andthe conflict in the Middle East. Regulatory Changes in relevant taxes, legal and administration regimes, accounting practice and government policies may adverselyaffect the financial performance of the Company. Reliance on key management The responsibility of overseeing the day-to-dayoperations andthe strategic management of the Company depends substantiallyon its senior management and its key personnel. There can be no assurance given that there will be no detrimental impact on the Companyif one or more of these employees cease their employment. Supply of Raw Materials The Company may dependon the supplyof raw materials to carry on elements of its business. Such supply may be disrupted because of weather, transportation and other matters outside the Company’s control. Product liability The Company provides products for use in TCMandfoodproducts to deliver TCM-based health benefits, which are used and/or consumed byhumans for therapeutic and other purposes. If the Company’s product(s) causes damage or loss of life, claims may be made against the Company that it has supplieddefective products. Sovereign Risk The Group’s operations willcontinue to include a focus on markets in China and South East Asia, including but not limited to Singapore andMalaysia. Possible sovereign risks associated with operating in China and these South East Asian nations include, without limitation, changes in the terms of legislation, changes to taxation rates andconcessions and changes in the ability to enforce legal rights. Any of these factors may, in the future, adverselyaffect the financial performance of the Company andthe market price of the Company’s Shares andlistedOptions. Intellectual Property Risks The Company willgive consideration to whether it will pursue patent protection in Singapore and other jurisdictions in relation to technologies it develops. However, there is no guarantee that any future patent applications filed bythe Company will not infringe competitor patents or that any such patent applications will be grantedby authorities in keyjurisdictions, given that patents on similar subject matter may have been granted. 19 Authorised by the Board of Directors